When Higher Risk Does Not Equal Greater Harm: Doing the Most Good in a Limited Pediatric Study Population

&
American Journal of Bioethics 20 (4):118-120 (2020)
  Copy   BIBTEX

Abstract

Volume 20, Issue 4, May 2020, Page 118-120.

Categories

Keywords

Reprint years

DOI

10.1080/15265161.2020.1730491

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 93,642

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

My notes

Similar books and articles

Flexibility Required: Balancing the Interests of Children and Risk in Drug Development for Rare Pediatric Conditions.Kathryn M. Porter, Anne Stevens & Benjamin S. Wilfond - 2020 - American Journal of Bioethics 20 (4):116-118.
Greater Than Minimal Risk, No Direct Benefit – Bridging Drug Trials and Novel Therapy in Pediatric Populations.Benjamin S. Wilfond, Devan M. Duenas & Liza-Marie Johnson - 2020 - American Journal of Bioethics 20 (4):102-103.
Bringing Known Drugs to Pediatric Research: Safety, Efficacy, and the Ambiguous Minor Increase in Minimal Risk.Akshay Sharma & Liza-Marie Johnson - 2020 - American Journal of Bioethics 20 (4):106-108.
The Use of Pediatric Extrapolation to Avoid Unnecessary Pediatric Clinical Trials.Robert M. Nelson - 2020 - American Journal of Bioethics 20 (4):114-116.
Clearing Muddy Waters: The Need to Reconceptualize Minor Increase over Minimal Risk in Pediatric Rare Disease Research.Devan M. Duenas, Benjamin S. Wilfond & Liza-Marie Johnson - 2020 - American Journal of Bioethics 20 (4):8-10.
Balancing Risk and Reward: Greater Research Oversight Is Appropriate for Novel Therapies for Children With Life-Limiting Illness.Yoram Unguru - 2020 - American Journal of Bioethics 20 (4):104-105.
Balancing Scientific Progress With Pediatric Protections: No Direct Benefit Now, But Potential Novel Therapy in the Future.Susannah W. Lee & Jessica C. Ginsberg - 2020 - American Journal of Bioethics 20 (4):108-110.
Ethical Drug Development for Rare Childhood Diseases: When There Are Limited But Promising Data in Adults, How to Choose Between Safety or Efficacy Studies?Liza-Marie Johnson, Devan M. Duenas & Benjamin S. Wilfond - 2020 - American Journal of Bioethics 20 (4):111-113.
Like Autism, Representation Falls on a Spectrum.Nanette Elster & Kayhan Parsi - 2020 - American Journal of Bioethics 20 (4):4-5.
Representing the Autism Spectrum.Robert Chapman & Walter Veit - 2020 - American Journal of Bioethics 20 (4):46-48.

Analytics

Added to PP
2020-03-25

Downloads
8 (#517,646)

6 months
17 (#859,272)

Historical graph of downloads
How can I increase my downloads?

Citations of this work

Add more citations

References found in this work

Add more references